Genes Involved in Invasion and Metastasis of Gastric Cancer Identified by Array-Based Hybridization and Serial Analysis of Gene ExpressionOue N.a · Aung P.P.a · Mitani Y.a · Kuniyasu H.b · Nakayama H.a · Yasui W.a
Departments of Molecular Pathology,aHiroshima University Graduate School of Biomedical Sciences, Hiroshima, and bNara Medical University, Kashihara, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Gastric cancer (GC) is still a serious health problem and remains the second most common type of fatal cancer worldwide. Comprehensive gene expression analyses may be useful to identify genes associated with invasion/metastasis in GC. Among them, array-based hybridization and serial analysis of gene expression (SAGE) are currently the most common approaches. Over the past 3 years, several large-scale gene expression studies with array-based hybridization and SAGE have been performed and several genes have been identified. This review describes genes associated with invasion/metastasis in GC which have been identified by array-based hybridization and SAGE. We compared the expression levels of the genes identified by array-based hybridization with our SAGE data. In addition, expression of the candidate genes obtained by SAGE was further investigated by quantitative RT-PCR of 40 GC samples. MIA and GW112 were overexpressed in 10 (25%) and 22 (55%) of 40 GC samples, and the overexpression of these two genes was associated with tumor stage, respectively. We also discuss the significance of HMGB1/amphoterin in invasion and metastasis of GC.
© 2005 S. Karger AG, Basel
- Terry MB, Gaudet MM, Gammon MD: The epidemiology of gastric cancer. Semin Radiat Oncol 2002;12:111–127.
- Hohenberger P, Gretschel S: Gastric cancer. Lancet 2003;362:305–315.
Fidler IJ: Critical determinants of human colon cancer metastasis; in Tahara E (ed): Molecular Pathology of Gastroenterological Cancer. Tokyo, Springer, 1997, pp 147–169.
- Ushijima T, Sasako M: Focus on gastric cancer. Cancer Cell 2004;5:121–125.
- Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, et al: Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996;14:1675–1680.
- Velculescu VE, Zhang L, Vogelstein B, Kinzler KW: Serial analysis of gene expression. Science 1995;270:484–487.
- El-Rifai W, Frierson HF Jr, Harper JC, Powell SM, Knuutila S: Expression profiling of gastric adenocarcinoma using cDNA array. Int J Cancer 2001;92:832–838.
- Hasegawa S, Furukawa Y, Li M, Satoh S, Kato T, Watanabe T, et al: Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res 2002;62:7012–7017.
- Hippo Y, Taniguchi H, Tsutsumi S, Machida N, Chong JM, Fukayama M, et al: Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 2002;62:233–240.
- Inoue H, Matsuyama A, Mimori K, Ueo H, Mori M: Prognostic score of gastric cancer determined by cDNA microarray. Clin Cancer Res 2002;8:3475–3479.
- Oue N, Hamai Y, Mitani Y, Matsumura S, Oshimo Y, Aung PP, et al: Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res 2004;64:2397–2405.
- El-Rifai W, Moskaluk CA, Abdrabbo MK, Harper J, Yoshida C, Riggins GJ, et al: Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 2002;62:6823–6826.
- Lee JY, Eom EM, Kim DS, Ha-Lee YM, Lee DH: Analysis of gene expression profiles of gastric normal and cancer tissues by SAGE. Genomics 2003;82:78–85.
- Oien KA, Vass JK, Downie I, Fullarton G, Keith WN: Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomach. Oncogene 2003;22:4287–4300.
- Yasui W, Oue N, Ito R, Kuraoka K, Nakayama H: Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci 2004;95:385–392.
- Kondo T, Oue N, Yoshida K, Mitani Y, Naka K, Nakayama H, et al: Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma. Cancer Res 2004;64:523–529.
Sobin LH, Wittekind CH (eds): TNM Classification of Malignant Tumors, ed 5. New York, Wiley-Liss, 1997, pp 59–62.
- Blesch A, Bosserhoff AK, Apfel R, Behl C, Hessdoerfer B, Schmitt A, et al: Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res 1994;54:5695–5701.
- Bosserhoff AK, Moser M, Hein R, Landthaler M, Buettner R: In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers. J Pathol 1999;187:446–454.
- Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, et al: Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997;57:3149–3153.
- Poser I, Tatzel J, Kuphal S, Bosserhoff AK: Functional role of MIA in melanocytes and early development of melanoma. Oncogene 2004;23:6115–6124.
- Zhang X, Huang Q, Yang Z, Li Y, Li CY: GW112, a novel antiapoptotic protein that promotes tumor growth. Cancer Res 2004;64:2474–2481.
- Shinozaki S, Nakamura T, Iimura M, Kato Y, Iizuka B, Kobayashi M, et al: Upregulation of Reg 1α and GW112 in the epithelium of inflamed colonic mucosa. Gut 2001;48:623–629.
- Poser I, Golob M, Buettner R, Bosserhoff AK: Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 2003;23:2991–2998.
- Bustin M, Lehn DA, Landsman D: Structural features of the HMG chromosomal proteins and their genes. Biochim Biophys Acta 1990;1049:231–243.
- Bianchi ME, Beltrame M, Paonessa G: Specific recognition of cruciform DNA by nuclear protein HMG1. Science 1989;243:1056–1059.
- Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, et al: Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002;196:163–170.
- Xiang YY, Wang DY, Tanaka M, Suzuki M, Kiyokawa E, Igarashi H, et al: Expression of high-mobility group-1 mRNA in human gastrointestinal adenocarcinoma and corresponding non-cancerous mucosa. Int J Cancer 1997;74:1–6.
- Czura CJ, Wang H, Tracey KJ: Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res 2001;7:315–321.
- Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248–251.
- Schmidt AM, Hofmann M, Taguchi A, Yan SD, Stern DM: RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Semin Thromb Hemost 2000;26:485–493.
- Rauvala H, Huttunen HJ, Fages C, Kaksonen M, Kinnunen T, Imai S, et al: Heparin-binding proteins HB-GAM (pleiotrophin) and amphoterin in the regulation of cell motility. Matrix Biol 2000;19:377–387.
- Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354–360.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.